Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC

INTRODUCTION: We present the results of a phase 2a trial of first-line avelumab (anti–programmed death-ligand 1 antibody) plus cetuximab (anti–EGFR antibody) in patients with advanced squamous NSCLC. METHODS: Patients with recurrent or metastatic squamous NSCLC received avelumab 800 mg (d 1 and 8),...

Descripción completa

Detalles Bibliográficos
Autores principales: Andric, Zoran, Gálffy, Gabriella, Cobo Dols, Manuel, Szima, Barna, Stojanovic, Goran, Petrovic, Marina, Felip, Enriqueta, Vicente Baz, David, Ponce Aix, Santiago, Juan-Vidal, Oscar, Szalai, Zsuzsanna, Losonczy, Gyorgy, Calles Blanco, Antonio, Bernabe, Reyes, García Ledo, Gema, Aguilar Hernández, Andrés, Duecker, Klaus, Zhou, Dongli, Schroeder, Andreas, Guezel, Guelseren, Ciardiello, Fortunato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883276/
https://www.ncbi.nlm.nih.gov/pubmed/36718142
http://dx.doi.org/10.1016/j.jtocrr.2022.100461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883276/
https://www.ncbi.nlm.nih.gov/pubmed/36718142
http://dx.doi.org/10.1016/j.jtocrr.2022.100461

Ejemplares similares